Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | MGAM | O43451 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 6/20 | 0.55 |
| ▸ | SI | P14410 | 6/20 | 0.55 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 0.55 |
| ▸ | GNRHR | P30968 | 8/20 | 0.52 |
| ▸ | PARP1 | P09874 | 5/20 | 0.50 |
| ▸ | TNKS | O95271 | 2/20 | 0.50 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31063829 | 1.00 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL31063846 | 0.84 | MGAM (0.68) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL22452313 | 0.84 | MGAM (0.68) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL3286051 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL31027910 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL21705584 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL22452564 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL22452316 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL31063825 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 | |
| SCHEMBL31027917 | 0.82 | HDAC6 (0.60) | HDAC6MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-03-04 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 101/4885MGAM 4661/4885GAA 1324/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 91/4885MGAM 3495/4885GAA 382/4885 |
| US-20210061769-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | HDAC6 107/4885MGAM 4630/4885GAA 1555/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 107/4885MGAM 4630/4885GAA 1555/4885 |
| US-10851066-B2 | 2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | HDAC6 101/4885MGAM 4661/4885GAA 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.